Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
Clinical trial NCT07685704 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07685704
- Sponsor
- Zhifeng Zhao, PhD
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2028-06-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.